Disease/Infection News

RSS

Research paper highlights the role of T-cells in HIV

Ryan Zurakowski, assistant professor of electrical and computer engineering at the University of Delaware, is co-author of a paper appearing in Nature Medicine on Jan. 12 highlighting the role of T-cells in HIV.

15 Jan 2014

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Pulmonary fibrosis is a condition where fibrotic or scarred tissue progressively develops in the lungs. In some cases the particular cause is known but in others it remains unknown and is given the term “idiopathic”.

14 Jan 2014

Study indicates some groups have specific genetic make-up that prevents from fighting off influenza

Research indicated that some Indigenous people such as in Alaska and Australia displayed limited immunity response to the effects of influenza.

13 Jan 2014

Meridian's TRU FLU assay gets FDA clearance for analytical sensitivity claim for avian Influenza H7N9 strain

Meridian Bioscience, Inc. today announced that the company's TRU FLU assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens.

10 Jan 2014

Scientists progress towards understanding how some bacterial cells escape being killed by antibiotics

Scientists have made an important advance in understanding how a subset of bacterial cells escape being killed by many antibiotics.

10 Jan 2014

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Findings of a preliminary study published in The Lancet Respiratory Medicine suggest that a patient’s own bone-marrow stromal (stem) cells could be used to treat multidrug-resistant (MDR) and extensively-drug (XDR) tuberculosis.

10 Jan 2014

Hussey Copper launches new line of home improvement products that fight deadly bacteria

Hussey Copper, a leader in copper manufacturing, with support from Lynn Tilton and Patriarch Partners, today launches a new line of home improvement products that fight deadly bacteria known to lurk on surfaces.

10 Jan 2014

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced interim data from a Phase 3 cholera challenge study of its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo.

10 Jan 2014

Study: HIV-specific poison kills persisting HIV-infected cells during antiretroviral therapy

A team including University of North Carolina and NIH scientists has demonstrated in a mouse model that an HIV-specific poison can kill cells in which the virus is actively reproducing despite antiretroviral therapy.

10 Jan 2014

Virginia Tech engineer receives NSF RAPID grant to study effects of antibiotic resistance genes on Colorado flood

The World Health Organization and the Center for Disease Control has recognized antibiotic resistance "as a critical health challenge of our time," said Amy Pruden, a Virginia Tech environmental engineer who is credited with pioneering the concept of antibiotic resistance genes as environmental pollutants.

10 Jan 2014

Researchers deploy potential new weapon against HIV

Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV - a combination therapy that targets HIV-infected cells that standard therapies cannot kill.

10 Jan 2014

Study provides details to help scientists design better vaccines for Plasmodium vivax

A form of malaria common in India, Southeast Asia and South America attacks human red blood cells by clamping down on the cells with a pair of proteins, new research at Washington University School of Medicine in St. Louis has revealed.

9 Jan 2014

TSRI researchers develop new fluid biopsy technique to identify patients at high risk of heart attack

A new "fluid biopsy" technique that could identify patients at high risk of a heart attack by identifying specific cells as markers in the bloodstream has been developed by a group of researchers at The Scripps Research Institute.

9 Jan 2014

Zyomyx's MyT4 point-of-care CD4 diagnostic test receives CE mark approval

Mylan, Inc. today announced that Zyomyx's MyT4 point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, an important step toward launching this innovative test and expanding access to affordable, accessible and reliable diagnostics for people living with HIV globally.

9 Jan 2014

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

ILiAD Biotechnologies, LLC, the French National Institute of Health and Medical Research subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille today announced the signing of scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1, developed by the laboratory of Professor Camille Locht. This license agreement covers patent rights from Institut Pasteur de Lille, Inserm, National University of Singapore and National University of Ireland Maynooth.

9 Jan 2014

Study identifies risk factors linked with non-fatal overdose among HIV-infected Russians

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have identified that injection frequency and taking anti-retroviral therapy for HIV are risk factors for nonfatal drug overdoses among Russians who are HIV positive and inject drugs.

9 Jan 2014

Daily antibiotic use is effective for preventing recurrent urinary tract infections in women

While daily antibiotic use is the most effective method for preventing recurrent urinary tract infections in women, daily cranberry pills, daily estrogen therapy and monthly acupuncture treatments also have benefits that may be preferable for some patients, according to a new study by researchers at the Los Angeles Biomedical Research Institute.

9 Jan 2014

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Cryptosporidium parvum is one of the most common enteropathogens to affect humans in the world. The protozoan parasite causes a gut infection referred to as cryptosporidiosis.

8 Jan 2014

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.

8 Jan 2014

First patient enrolled in the North American Phase 3 clinical trials for investigational flu treatment drug

BioDefense Therapeutics—a Joint Product Management office within the U.S. Department of Defense—announced the first patient enrolled in the North American Phase 3 clinical trials for favipiravir (T-705a). The drug is an investigational flu treatment candidate with broad-spectrum potential being developed by BD Tx through a contract with Boston-based MediVector, Inc.

7 Jan 2014

Disease/Infection News

Research paper highlights the role of T-cells in HIV

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Study indicates some groups have specific genetic make-up that prevents from fighting off influenza

Meridian's TRU FLU assay gets FDA clearance for analytical sensitivity claim for avian Influenza H7N9 strain

Scientists progress towards understanding how some bacterial cells escape being killed by antibiotics

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Hussey Copper launches new line of home improvement products that fight deadly bacteria

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

Study: HIV-specific poison kills persisting HIV-infected cells during antiretroviral therapy

Virginia Tech engineer receives NSF RAPID grant to study effects of antibiotic resistance genes on Colorado flood

Researchers deploy potential new weapon against HIV

Study provides details to help scientists design better vaccines for Plasmodium vivax

TSRI researchers develop new fluid biopsy technique to identify patients at high risk of heart attack

Zyomyx's MyT4 point-of-care CD4 diagnostic test receives CE mark approval

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

Study identifies risk factors linked with non-fatal overdose among HIV-infected Russians

Daily antibiotic use is effective for preventing recurrent urinary tract infections in women

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

First patient enrolled in the North American Phase 3 clinical trials for investigational flu treatment drug

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News